Table 1.
Clinical profiles of 272 patients with Hepatitis B infection
| Variables | CHB (n = 128) | CHB + MAFLD (n = 144) | Total (n = 272) | P value |
|---|---|---|---|---|
| Male, n (%) | 64 (50.0) | 92 (63.9) | 156 (57.4) | 0.021* |
| Age (years) | 47 (36–54) | 44 (38–53) | 44 (37–53) | 0.898 |
| Family history of HBV, n (%) | 65 (50.8) | 73 (50.7) | 138 (50.7) | 0.989 |
| Diabetes, n (%) | 8 (6.3) | 23 (16.0) | 31 (11.4) | 0.012* |
| Cirrhosis, n (%) | 10 (7.8) | 24 (16.7) | 34 (12.5) | 0.028* |
| Hepatocellular carcinoma, n (%) | 7 (5.5) | 7 (4.9) | 14 (5.1) | 0.821 |
| BMI (kg/m2) | 23.9 (22.1–25.3) | 25.1 (24.2–26.5) | 24.6 (23.1–26.0) | < 0.001* |
| Overweight/obesitya, n (%) | 54 (42.2) | 113 (78.5) | 167 (61.4) | < 0.001* |
| Waist-to-hip ratio | 0.88 (0.83–0.92) | 0.89 (0.84–0.96) | 0.89 (0.83–0.95) | 0.142 |
| CAP values (dB/m) | 209 (186–227) | 273 (259–295) | 250 (214–274) | < 0.001* |
| LSM values (kPa) | 5.5 (4.5–7.8) | 6.7 (5.1–8.5) | 6.2 (4.6–8.1) | 0.233 |
| ALT (U/L) | 28.0 (19.3–37.0) | 29.0 (21.3–43.0) | 29.0 (21.0–39.0) | 0.708 |
| Elevated ALTb, n (%) | 22 (17.2) | 41 (28.5) | 63 (23.2) | 0.028* |
Data are expressed as median (IQR) or number (%)
*Statistically significant at P < 0.05
BMI Body mass index, CAP Controlled attenuation parameter, LSM Liver stiffness measurement, ALT Alanine aminotransferase
aThe study included Chinese participants, with overweight/obesity defined as BMI ≥ 24 kg/m2
bElevated ALT was considered when exceeding the local upper limit of normal (ULN), with ALT > 40 U/L